exRNAdisease

Entry Detail

---



General Information

Database ID: exR0274640 RNA Name: hsa-miR-214-3p RNA Type: miRNA Chromosome: chr1 Starnd: - Coordinate: Start Site(bp): 172138816 End Site(bp): 172138837 External Links: hsa-miR-214-3p

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE22981 Description: Circulating miRNAs as biomarkers and potential functional mediators of early stage breast cancer Experimental Design: Cancer vs Control Case Disease Type: Breast Cancer Case Disease SubType: Early satge breast cancer Case Sample: Breast Cancer Control Sample: Control Number of Case: 20 Number of Control: 20 Number of Samples: 40

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand MTMR12 chr5 32226994 32312987 - AP3M1 chr10 74120255 74151063 - AMER1 chrX 64185117 64205708 - GDI1 chrX 154436913 154443467 + RPUSD1 chr16 784974 788397 - SMG5 chr1 156249224 156282825 - DHX36 chr3 154272546 154324487 - PIP5K1C chr19 3630183 3700479 - C19orf47 chr19 40319536 40348527 - MTMR3 chr22 29883155 30030866 + ABHD2 chr15 89087459 89202355 + MAPKAPK2 chr1 206684944 206734283 + RHPN1 chr8 143368876 143384221 + HDLBP chr2 241227264 241317061 - ARHGAP35 chr19 46860997 47005077 + YWHAB chr20 44885702 44908532 + WDR5 chr9 134135365 134159968 + RPS6KA1 chr1 26529761 26575030 + JPT1 chr17 75135248 75168281 - SEC61A1 chr3 128051641 128071683 + TMEM161B chr5 88189633 88269476 - NECTIN1 chr11 119623408 119729200 - SOX11 chr2 5692384 5701385 + MYH9 chr22 36281277 36388067 - RAB15 chr14 64945814 64973226 - PLAGL2 chr20 32192504 32207743 - TGIF2 chr20 36573488 36593950 + NRIP1 chr21 14961235 15065936 - LYSMD2 chr15 51723011 51751585 - KMT2D chr12 49018975 49059774 - miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0000540 chr14 55799534 55821940 + hsa_circ_0001168 chr20 47691321 47707559 + hsa_circ_0001146 chr20 34241449 34246936 - hsa_circ_0000799 chr17 65941524 65972074 + lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC008040.1 chr3 169939353 169966734 - AC010442.1 chr5 466124 473098 - AC016876.2 chr17 7581964 7584086 - AC068790.9 chr12 124085761 124088598 + AC109460.3 chr16 28974804 28990775 + ADAMTSL4-AS1 chr1 150560202 150574552 - AL031282.2 chr1 1702736 1737688 - AL160006.1 chr1 110058340 110062555 + EPB41L4A-AS1 chr5 112160526 112164818 + FGD5-AS1 chr3 14920347 14948424 - LINC00665 chr19 36313067 36331770 - LINC01535 chr19 37251885 37265535 + MIR17HG chr13 91347820 91354579 + NEAT1 chr11 65422774 65445540 + POLR2J4 chr7 43940895 44019175 - SNHG16 chr17 76557764 76565348 + STAG3L5P-PVRIG2P-PILRB chr7 100336104 100367831 + XIST chrX 73820649 73852723 - Display:

Experiment Detail

GEO ID: GSE22981 Sample Source: Blood Source Fraction: Plasma Platform: GPL8179 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 801 Sample treatment protocol: NA RNA Extract protocol: Total RNA, including miRNA from plasma, was isolated using the miRNeasy kit (Qiagen) with minor modifications. RNA library preparation protocol: Two hundred ng of total RNA from each sample were labeled and hybridized on Human v2 MicroRNA Expression BeadChips (Cat. no. MI-102-1024; Illumina).

Reference

PMID: 21060830 Title: A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer Author: Zhao H, Shen J, Medico L, Wang D, Ambrosone CB, Liu SBACKGROUND: To date, there are no highly sensitive and specific minimally invasive biomarkers for detection of breast cancer at an early stage. The occurrence of circulating microRNAs (miRNAs) in blood components (including serum and plasma) has been repeatedly observed in cancer patients as well as healthy controls. Because of the significance of miRNA in carcinogenesis, circulating miRNAs in blood may be unique biomarkers for early and minimally invasive diagnosis of human cancers. The objective of this pilot study was to discover a panel of circulating miRNAs as potential novel breast cancer biomarkers. METHODOLOGY/PRINCIPAL FINDINGS: Using microarray-based expression profiling followed by Real-Time quantitative Polymerase Cycle Reaction (RT-qPCR) validation, we compared the levels of circulating miRNAs in plasma samples from 20 women with early stage breast cancer (10 Caucasian American (CA) and 10 African American (AA)) and 20 matched healthy controls (10 CAs and 10 AAs). Using the significance level of p<0.05 constrained by at least two-fold expression change as selection criteria, we found that 31 miRNAs were differentially expressed in CA study subjects (17 up and 14 down) and 18 miRNAs were differentially expressed in AA study subjects (9 up and 9 down). Interestingly, only 2 differentially expressed miRNAs overlapped between CA and AA study subjects. Using receiver operational curve (ROC) analysis, we show that not only up-regulated but also down-regulated miRNAs can discriminate patients with breast cancer from healthy controls with reasonable sensitivity and specificity. To further explore the potential roles of these circulating miRNAs in breast carcinogenesis, we applied pathway-based bioinformatics exploratory analysis and predicted a number of significantly enriched pathways which are predicted to be regulated by these circulating miRNAs, most of which are involved in critical cell functions, cancer development and progression. CONCLUSIONS: Our observations from this pilot study suggest that the altered levels of circulating miRNAs might have great potential to serve as novel, noninvasive biomarkers for early detection of breast cancer. Journal: PLoS One. 2010 Oct 29;5(10):e13735. Description: The objective of this pilot study was to discover a panel of circulating miRNAs as potential novel breast cancer biomarkers.